Literature DB >> 2993493

Comparison of various serological methods and diagnostic kits for the detection of acute, recent, and previous rubella infection, vaccination, and congenital infections.

G Enders, F Knotek, U Pacher.   

Abstract

The antibody development after natural rubella infection and rubella vaccination has been followed in 802 sera from 493 patients and 71 sera from 22 vaccinees. Also examined were 67 sera from 28 infants with rubella embryopathy and sera from 50 children with presumed prenatal infection. In addition, 777 sera from 641 patients tested for routine rubella diagnosis were studied. Anamnestic information was available from all these patients. These sera were assayed for IgM antibody detection by sucrose density gradient (SDG), the commercial ELISAs (Enzygnost IgM and Rubazyme M), and the non-commercial anti-my-hemadsorption immunosorbent technique (HIT). For the determination of IgG antibodies the hemagglutination inhibition test (HAI), the commercial ELISAs (Enzygnost IgG, Rubazyme), and a single radial hemolysis test (SRH) were used. The SDG and HIT were less sensitive for IgM antibody detection than the two ELISAs, particularly when IgM concentrations were low. In total 26.5% of the IgM results with the newer tests were discordant with SDG, but only 0.5-1.3% of these results were not explicable when the clinical data was considered. Problems were encountered with all IgM assay systems used. For the detection of rubella antibodies after acute infection and vaccination the ELISA Enzygnost IgG was as sensitive as the HAI whereas the ELISA Rubazyme and SRH detected antibodies with some delay. Corresponding results with all tests were found more than 25 days after acute infection and more than 50 days after vaccination. All methods can be used for detection of antibodies in infants with rubella embryopathy. The results of this study suggest that certain combinations of tests can be used for the reliable detection of rubella infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993493     DOI: 10.1002/jmv.1890160303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  A silver enhanced, gold labelled, immunosorbent assay for detecting antibodies to rubella virus.

Authors:  N Patel; B F Rocks; M P Bailey
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 2.  Rubella vaccines: past, present and future.

Authors:  J M Best
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

3.  Evaluation of a latex agglutination test for screening antibodies to rubella virus.

Authors:  P León; F de Ory; C Domingo; J A López; J M Echevarría
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

4.  Accuracy of single radial hemolysis test for rubella immunity when internal reference standards are used to estimate antibody levels.

Authors:  F E Nommensen
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

5.  Prenatal diagnosis of intrauterine rubella.

Authors:  G Enders; W Jonatha
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

6.  Rubella embryopathy after previous maternal rubella vaccination.

Authors:  G Enders; A Calm; J Schaub
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

7.  Recent rubella virus infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; I Seppälä
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

8.  Rubella IgG total antibody avidity and IgG subclass-specific antibody avidity assay and their role in the differentiation between primary rubella and rubella reinfection.

Authors:  G Enders; F Knotek
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

9.  Detection of specific IgG and IgM antibodies in the haemagglutination inhibition test and the enzyme-linked immunoassay for the diagnosis of rubella infection.

Authors:  M C Maroto Vela; M C Bernal Zamora; A Levya Garcia; G Piédrola
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.